Identify the Pathogen. Pick the Right Drug. Same Day.
Built for the patient your culture keeps missing. 10 evidence-curated uropathogens — including fungal organisms culture routinely misses — from a single specimen.
Standard urine culture misses up to a third of true uropathogens — fastidious organisms, fungal species, polymicrobial infections, and patients already started on empirical antibiotics. Recurrent UTI patients pay for that miss with months of failed therapy.
Our UTI panel resolves all 10 targets from a single tube in 24–48 hours — so the first report your stewardship pharmacist sees already has the organism-level answer.
The clinical weight behind this panel.
Industry statistics from public-health bodies and peer-reviewed literature — context for why this testing matters.
One of the most common bacterial infections in outpatient medicine.
Driving a significant share of empiric antibiotic prescribing.
Pathogen-level identification reshapes recurrence workups.
Why empiric therapy increasingly misses the target.
Figures reflect publicly reported epidemiology and clinical literature for context only. They are not performance claims for the Chaseville Labs assay. See individual citations from the U.S. Centers for Disease Control and Prevention, World Health Organization, National Institutes of Health, and peer-reviewed journals.
Conditions, syndromes & infections covered.
The clinical scenarios where this panel is the right call — built around the differential your providers are actually working through.
Complicated & Recurrent UTI
4≥2 infections in 6 months or ≥3 in 12 months — culture often misses the shifting or persistent organism driving recurrence.
Diabetes, pregnancy, structural anomalies, kidney transplant, or immunocompromise where standard culture under-performs.
Polymicrobial and biofilm-driven infections — the most common healthcare-associated infection.
Symptomatic patient with negative urine culture — the classic frustrated rUTI patient.
Severe & Healthcare-Associated UTI
4Kidney infection and bloodstream extension — every hour of inappropriate empirical therapy raises mortality.
ESBL, CRE, MRSA, and VRE uropathogens — common in long-term care and post-instrumentation patients.
Species-level Candida ID — C. glabrata, C. krusei, and C. auris are intrinsically less susceptible to fluconazole.
Untreated infection in pregnancy raises preterm labor and pyelonephritis risk — broad coverage matters.
10 targets, resolved from a single specimen.
Each organism below is reported individually as Detected, Not Detected, or Inconclusive — grouped here by pathogen class for clinical scanability.
Bacteria
12 targetsFungi
3 targetsEvidence-curated for the patients who fail empirical therapy.
Every target on this panel is here for a documented clinical reason — drawn from the geriatric, long-term-care, catheter-associated, and recurrent-UTI literature. No filler organisms, no marketing additions.
- 01
Escherichia coli
The most frequent uropathogen overall, though less dominant in institutionalized elderly patients than in the general public.
- 02
Klebsiella pneumoniae
Highly prevalent in long-term care settings and notoriously prone to multi-drug resistance.
- 03
Proteus mirabilis
Spikes heavily in geriatric populations; intimately linked with incontinence, catheter biofilms, and struvite kidney stones.
- 04
Enterococcus faecalis
A primary Gram-positive driver of healthcare- and device-associated UTIs in older adults.
- 05
Pseudomonas aeruginosa
Common in patients with a history of frequent antibiotic use or indwelling medical devices.
- 06
Staphylococcus aureus
Critical to catch — its presence in geriatric urine strongly signals possible bloodborne infection or MRSA seeding.
- 07
Streptococcus agalactiae (GBS)
Famous in pregnancy, but highly opportunistic in diabetic or bedridden elderly patients.
- 08
Candida albicans
Fungal tracking is useful here because chronic antibiotic exposure frequently leads to bladder colonization.
- 09
Candida glabrata
The second most common urinary fungus — vital to differentiate because it is often resistant to standard fluconazole.
- 10
Candida tropicalis
Covers the remaining major non-albicans fungal threat in this population.
Culture was built for a different century.
Multiplex real-time PCR resolves what culture and rapid antigen miss — fastidious organisms, polymicrobial infections, viruses, and resistance markers — from a single specimen.
Culture & rapid antigen
- 3–5 daysPatient empirically treated before any answer arrives
- Misses fastidious & viral organismsNo growth ≠ no infection
- Single-organism biasPolymicrobial infections under-reported
- No resistance dataSusceptibilities arrive a day later, if at all
- Specimen-quality dependentPre-treated patients culture negative
UTI Panel on Bio-Rad CFX384
- 24–48 hoursMost reports back the next clinical day
- 10 targets, one runBacterial, viral, fungal, and parasitic in a single multiplex
- Detects what culture can'tFastidious organisms, viruses, and polymicrobial infections, all reported individually
- Validated LDTCLIA-certified, internally controlled, per-target Detected / Not Detected reporting
Per-target results, with clinical context.
Every analyte is reported individually as Detected, Not Detected, or Inconclusive. What a Detected result means clinically depends on which category the target falls into:
Gram-negative rods (E. coli, Klebsiella, Proteus) dominate uncomplicated UTI and direct first-line therapy. Pseudomonas, Acinetobacter, Enterococcus, and Staph aureus typically signal complicated, catheter-associated, or healthcare-acquired infection and warrant broader coverage and source control.
Candiduria in a symptomatic, immunocompromised, or catheterized patient may represent true infection rather than colonization. C. glabrata, C. krusei, and C. auris are intrinsically less susceptible to fluconazole and should prompt species-directed antifungal selection.